Wein, Ferrante Comment on Telehealth Changes For Medicare Advantage Providers
27 April 2020
Of Counsel Emily Wein and Senior Counsel Thomas Ferrante were quoted in a Part B News article, “CMS lets MA providers do telehealth risk adjustment; tight documentation advised,” about a change in CMS policy allowing Medicare Advantage providers to do risk adjustment by telehealth during the coronavirus pandemic.
Wein said guidance on telehealth from Medicare administrative contractors (MAC) is helpful, but suggests that MA providers new to telehealth go a step further and walk through their reasoning in notes. “Maybe in the initial stages, providers should take extra efforts to show professional judgment was exercised in using telehealth, not just assert ‘the MAC said I could,’” she said.
Ferrante said providers should not offer a provisional diagnosis for risk adjustment purposes contingent on the patient coming in when the current emergency is lifted. “I don’t know if the subsequent visit would be reimbursable,” he said. “If you think the provider had enough under the current emergency guidance, what would be the justification for bringing the patient in again?”
(Subscription required.)
Wein said guidance on telehealth from Medicare administrative contractors (MAC) is helpful, but suggests that MA providers new to telehealth go a step further and walk through their reasoning in notes. “Maybe in the initial stages, providers should take extra efforts to show professional judgment was exercised in using telehealth, not just assert ‘the MAC said I could,’” she said.
Ferrante said providers should not offer a provisional diagnosis for risk adjustment purposes contingent on the patient coming in when the current emergency is lifted. “I don’t know if the subsequent visit would be reimbursable,” he said. “If you think the provider had enough under the current emergency guidance, what would be the justification for bringing the patient in again?”
(Subscription required.)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”